TIGIT and non-small cell lung carcinoma: In a first-line therapy for non-small cell lung cancer, atezolizumab plus tiragolumab (an anti-TIGIT antibody) showed superior clinical efficacy as compared with anti-PD-L1 therapy alone recently (52).